Updated:
Perceptive Xontogeny Venture Funds
Perceptive Advisors established its Venture Capital strategy with the launch of Perceptive Xontogeny Venture Fund, LP in 2018 and closed Perceptive Xontogeny...
Perceptive Xontogeny Venture Funds
Perceptive Advisors established its Venture Capital strategy with the launch of Perceptive Xontogeny Venture Fund, LP in 2018 and closed Perceptive Xontogeny Venture Fund II, LP in 2021. The strategy manages over $700 million dedicated to financing early-stage life sciences companies, primarily seed and Series A, with select later-stage financings. It partners with founders and invests in differentiated technologies seeking significant therapeutic impact on serious disease or improvements in healthcare delivery, across biotechnology, medtech, healthtech, digital health and healthcare tools/services.
General information
Firm type
Venture Capital
Year founded
2017
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Additional offices
Boston, MA, United States · Tiburon, CA, United States
Principals
Chris Garabedian
CEO, Perceptive Xontogeny Venture Funds
Joe Edelman
Founder and CEO, Perceptive Advisors
Sector focus
Frequently asked questions
Who runs investment decisions at Perceptive Xontogeny Venture Funds?
Chris Garabedian serves as CEO and leads investment decisions for the venture funds. He previously founded Xontogeny, a biotech accelerator, and has a background in life sciences entrepreneurship. The fund is part of Perceptive Advisors, founded by Joe Edelman, but Garabedian directs the venture-focused portfolio.
Does Perceptive Xontogeny participate in fund commitments or only direct deals?
The firm focuses exclusively on direct venture capital investments, primarily leading or co-leading rounds in early-stage biotech companies. They do not commit to other funds. Their model involves hands-on portfolio company building.
Which sectors does Perceptive Xontogeny explicitly focus on?
The fund invests exclusively in life sciences, with a heavy emphasis on therapeutics, including gene therapy, cell therapy, and precision medicine. They also invest in diagnostics and platforms. They avoid non-life sciences sectors like tech or energy.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: